SecBot SecBot
SECBOTREPLAY Home › Report › KRYS

KRYS · Krystal Biotech reported Q3 2026 VYJUVEK revenue of $127.3M, up 30% YoY…

Krystal Biotech, Inc. · PRESS-RELEASE filed Nov 2, 2026 at 07:00 ET

At the news

BULLISHIMPACT 6/10

PRESS-RELEASE filed Nov 2, 2026 at 07:00 ET

Krystal Biotech reported Q3 2026 VYJUVEK revenue of $127.3M, up 30% YoY and above the $126.5M consensus. GAAP diluted EPS of $2.05 beat the $1.92 consensus. The company also authorized a $400M share repurchase program and provided positive KB113 clinical data in Gorlin syndrome.

  • Q3 2026 VYJUVEK net product revenue of $127.3M, up 30% YoY from $97.8M
  • GAAP diluted EPS of $2.05, above consensus estimate of $1.92
  • Gross margin of 94% for the quarter
  • Board authorized share repurchase program of up to $400 million

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access